Maurie Markman1. 1. The University of Texas MD Anderson Cancer Center, Department of Gynecologic Medical Oncology, Houston, Texas 77005, USA. mmarkman@mdanderson.org
Abstract
BACKGROUND: There is a critical need to develop effective new strategies for the management of patients with advanced epithelial ovarian cancer. OBJECTIVE: The purpose of this manuscript is to discuss the rationale for, and initial clinical results of, attempts to interfere with the process of tumor angiogenesis as a novel treatment paradigm in ovarian cancer. RESULTS/ CONCLUSION: Phase II clinical trial data provide strong support for the suggestion that antiangiogenic agents have the potential to play a major therapeutic role in this difficult malignancy. It is reasonable to acknowledge that the pending results of several ongoing evidence-based randomized Phase III trials that directly explore the clinical utility of this strategy may substantially alter the current standard management approaches in advanced ovarian cancer.
BACKGROUND: There is a critical need to develop effective new strategies for the management of patients with advanced epithelial ovarian cancer. OBJECTIVE: The purpose of this manuscript is to discuss the rationale for, and initial clinical results of, attempts to interfere with the process of tumor angiogenesis as a novel treatment paradigm in ovarian cancer. RESULTS/ CONCLUSION: Phase II clinical trial data provide strong support for the suggestion that antiangiogenic agents have the potential to play a major therapeutic role in this difficult malignancy. It is reasonable to acknowledge that the pending results of several ongoing evidence-based randomized Phase III trials that directly explore the clinical utility of this strategy may substantially alter the current standard management approaches in advanced ovarian cancer.
Authors: Kian Behbakht; Michael W Sill; Kathleen M Darcy; Stephen C Rubin; Robert S Mannel; Steven Waggoner; Russell J Schilder; Kathy Q Cai; Andrew K Godwin; R Katherine Alpaugh Journal: Gynecol Oncol Date: 2011-07-12 Impact factor: 5.482
Authors: X Chen; T Paranjape; C Stahlhut; T McVeigh; F Keane; S Nallur; N Miller; M Kerin; Y Deng; X Yao; H Zhao; J B Weidhaas; F J Slack Journal: Oncogene Date: 2014-06-09 Impact factor: 8.756